Efficacy and Safety of BNP105 in the Treatment of Recurrent Aphthous Stomatitis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy and safety of BNP105 in the treatment of recurrent aphthous stomatitis.

Official Title
-----------------
National, Multicenter, Randomized, Double-blind, Pilot Study to Evaluate the Efficacy and Safety of BNP105 in the Treatment of Recurrent Aphthous Stomatitis

Conditions
-----------------
Aphthous Stomatitis

Intervention / Treatment
-----------------
* Drug: BNP105 (25 + 25 + 15)
* Other: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Ability to confirm voluntary participation and agree to all trial purposes by signing and dating the informed consent forms; Age greater than or equal to 12 years; One minor recurrent aphthous stomatitis with onset of symptoms within 48 hours; Moderate to severe baseline pain, with VAS ≥ 60 mm (EVA scale 0-100 mm). Exclusion Criteria: Any clinical findings that, in the judgment of the investigator, may interfere with the safety of research participants; Participants diagnosed with: Behcet's disease, rheumatoid arthritis, systemic lupus erythematosus, reactive arthritis, Reiter's syndrome, Crohn's disease, ulcerative colitis); Participants with diseases that affect healing (e.g. diabetes); Immunocompromised participants; Participants with aphthous herpetiform ulceration or major aphthous ulceration; Participants using medication to treat oral ulcerations (systemic or local); Participants who used analgesics or anti-inflammatory drugs in the 6 hours prior to the beginning of the study; Participants who used systemic antibiotics in the 2 weeks prior to the beginning of the study; Participants using medications that can confuse pain assessment (psychotropics, antidepressants and sedative-hypnotics), except when on a stable dose for at least 30 days prior to the screening visit, and the dose cannot be changed during the clinical trial; Participants with current smoking habits. Participants who are pregnant, breastfeeding or planning to get pregnant or female participants with the potential to become pregnant who are not using a reliable method of contraception; Known hypersensitivity to the formula components used during the clinical trial; Participants with current or medical history of cancer in the last 5 years; Participants who participated in other research protocol in the last 12 months, unless the investigator judges that there may be a direct benefit to it.

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: BNP105 (25 + 25 + 15)<br>Up to six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops. | Drug: BNP105 (25 + 25 + 15)<br>* BNP105 oral suspension, 25 mg + 25 mg + 15 mg, oral. Up to six applications per day.<br>|
| Placebo Comparator: Placebo<br>Up to six applications per day. The number of drops varies according to the ulcer diameter: 1 to 3 mm: 1 drop; 3 to 6 mm: 2 drops; greater than 6 mm: 3 drops. | Other: Placebo<br>* Placebo. Up to six applications per day.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the change in pain intensity after the first application. | Difference in pain intensity 3 and 10 minutes after the first application of the medication compared to baseline, measured by the VAS scale. The VAS consists of a 100 mm line, with two end points representing 0 (no pain) and 100 (Worst Possible Pain). | 3 and 10 minutes | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To assess the change in pain intensity after 3 days of treatment. | Difference in pain intensity after 3 days of treatment compared to baseline. Pain intensity will be evaluated by the Visual Analogue Scale (VAS). The VAS consists of a 100 mm line, with two end points representing 0 (no pain) and 100 (Worst Possible Pain). | 3 days | 
| To assess the pain intensity daily after breakfast, lunch and dinner. | Pain intensity will be evaluated daily after breakfast, lunch and dinner by the Numeric Pain Rating Scale (NPRS). The NPRS is an 11-point scale scored from 0-10 representing 0 (no pain) and 10 (Worst Possible Pain). | 7 days | 
| To assess the pain intensity daily at night. | Pain intensity will be evaluated daily at night by the Numeric Pain Rating Scale (NPRS). The NPRS is an 11-point scale scored from 0-10 representing 0 (no pain) and 10 (Worst Possible Pain). | 7 days | 
| To assess the oral health-related quality of life | The oral health-related quality of life will be evaluated daily at night by the adapted Oral Health Impact Profile (OHIP) questionary. | 7 days | 
| Percentage of participants healed after 3 days of treatment. | Percentage of participants healed after 3 days of treatment, defined as ulcer diameter = 0 mm and pain intensity = 0, measured by the VAS scale. The VAS consists of a 100 mm line, with two end points representing 0 (no pain) and 100 (Worst Possible Pain). | 3 days | 
| Percentage of participants with no pain after 3 days of treatment. | Percentage of participants with no pain after 3 days of treatment, defined as pain intensity = 0, measured by the VAS scale. The VAS consists of a 100 mm line, with two end points representing 0 (no pain) and 100 (Worst Possible Pain). | 3 days | 
| Global assessment of treatment by participant after 3 days of treatment | The global evaluation of the treatment after 3 days of treatment will be evaluated by the categorical scale of 5 points representing 0 = very bad, 1 = bad, 2 = indifferent, 3 = good and 4 = very good. | 3 days | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Aphthous Stomatitis